« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | Zolinza |
| Generic Name: | vorinostat |
| Code Name: | MK0683 |
| Company: | Merck Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Zolinza (news articles), which is an approved drug for cutaneous T-cell lymphoma, is also being studied in combination with Velcade…
| Brand Name: | Actimid |
| Generic Name: | pomalidomide |
| Code Name: | CC-4047 |
| Company: | Celgene |
| FDA Clinical Phase: | 1/2 |
| Brand Name: | |
| Generic Name: | |
| Code Names: | MAGE-A3 and NY-ESO-1 |
| Company: | University of Arkansas |
| FDA Clinical Phase: | 2/3 |
Description:
The hope is that the peptide vaccines will stimulate the immune system to attack and kill the myeloma cells. The purpose is to…
| Brand Name: | |
| Generic Name: | ridaforolimus (formerly deforolimus) |
| Code Name(s): | AP23573 |
| Company: | Ariad Pharmaceuticals & Merck |
| FDA Clinical Phase: | 1 |
Description:
Ridaforolimus, formerly known as deforolimus, is a drug used to treat soft tissue and bone sarcomas. It is also being studied in…
| Brand Name: | |
| Generic Name: | |
| Code Name: | CX-4945 |
| Company: | Cylene |
| FDA Clinical Phase: | 1 |
Description:
CX-4945 is an oral anti-cancer agent. It inhibits CK2, an enzyme that plays a role in the development of cancerous cells through cellular processes such as cell…
| Brand Name: | |
| Generic Name: | Marizomib, salinosporamide A |
| Code Name: | NPI-0052 |
| Company: | Nereus Pharmaceuticals |
| FDA Clinical Phase: | 1 |
Description:
Marizomib (NPI-0052, salinosporide A) is a novel proteasome inhibitor that suppresses tumor growth by inhibiting the enzymes that break down important proteins in cancerous…
